Trial Profile

Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients

Status: Suspended

Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab (Primary)
Indications Breast cancer
Focus Adverse reactions; Biomarker

Most Recent Events

12 May 2016 Planned End Date changed from 1 Mar 2016 to 1 Aug 2016.
12 May 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Aug 2016.
30 Mar 2016 Planned number of patients changed from 100 to 50 as per ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com